MedTrace Logo

Characterization of Cerebral Tau Aggregates With 18F-RO6958948 PET in the ALFA Population

NCT04482660 · Status: ENROLLING_BY_INVITATION · Phase: NA · Type: INTERVENTIONAL · Enrollment: 100

Last updated 2025-05-31

No results posted yet for this study

Summary

This study will characterize tau tracer retention by Positron Emission Tomography (PET) as a function of amyloid levels transversally and longitudinally.

Conditions

Interventions

PROCEDURE

Positron emission tomography with 18F-RO6958948

tau PET ()

Sponsors & Collaborators

  • Hoffmann-La Roche

    collaborator INDUSTRY

  • Hospital Clinic of Barcelona

    collaborator OTHER

  • Barcelonabeta Brain Research Center, Pasqual Maragall Foundation

    lead OTHER

Study Design

Allocation
NA
Purpose
OTHER
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
45 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2021-03-29
Primary Completion
2025-12-31
Completion
2025-12-31

Countries

  • Spain

Study Locations

More Related Trials

Entities

Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT04482660 on ClinicalTrials.gov